Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by R013013Con May 25, 2020 11:15am

239 Views

Post# 31068775

RE:RE:$0.55 - wall broken

10bagger10 wrote:
I think it would be a mistake to bet against this stock/emerging industry and market in general.

QE infinity is here and markets are awash in cash. Pyscadellics have got a big run in the making

Fully expect MMED to succeed, but I think over the next few months you may be able to find some lower entry points.

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute